Noradrenaline Plus Albumin in Hepatorenal Syndrome Management

Diagnostic Criteria for Hepatorenal Syndrome

Diagnosis of hepatorenal syndrome requires cirrhosis with ascites, acute kidney injury stage 2 or 3 according to KDIGO criteria, no response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin, absence of shock, no recent use of nephrotoxic drugs, and no macroscopic signs of structural kidney injury, as recommended by the American Association for the Study of Liver Diseases 1
The diagnostic criteria for hepatorenal syndrome include acute kidney injury stage 2 or 3 according to KDIGO criteria, with a strength of evidence level of high 1

The American Association for the Study of Liver Diseases recommends terlipressin plus albumin as the reference treatment for hepatorenal syndrome, with a strength of evidence level of high 2, 3
Terlipressin is administered at an initial dose of 0.5-1 mg IV every 4-6 hours, with gradual increase to maximum 2 mg every 4-6 hours if serum creatinine doesn't decrease by >25%, as recommended by the European Association for the Study of the Liver 2, 4

Noradrenaline is a reliable alternative to terlipressin in patients with central venous access, with a success rate of 83% in reversing type 1 hepatorenal syndrome, as recommended by the Society of Critical Care Medicine 2, 1
Meta-analyses show no significant difference between terlipressin+albumin and noradrenaline+albumin in hepatorenal syndrome reversal or relapse rates, with a strength of evidence level of moderate 2

Albumin is administered at 1 g/kg before initiating vasoconstrictor treatment, followed by 20-40 g/day, as recommended by the American Association for the Study of Liver Diseases 2, 1
Albumin improves systemic hemodynamics by increasing cardiac output and through its antioxidant and anti-inflammatory properties, with a strength of evidence level of high 2

Midodrine plus octreotide plus albumin is less effective than noradrenaline and should not be the first choice when noradrenaline is available, as recommended by the European Association for the Study of the Liver 2
TIPS (transjugular intrahepatic portosystemic shunts) may improve renal function in some patients but has limited applicability due to contraindications, as recommended by the American Association for the Study of Liver Diseases 5

Monitor serum creatinine, mean arterial pressure, urine output, and serum sodium concentration to assess response to therapy, as recommended by the European Association for the Study of the Liver 4
Response is characterized by progressive reduction in serum creatinine, increase in arterial pressure, urine volume, and serum sodium, with a strength of evidence level of high 4

Patients with cirrhosis and ascites should undergo diagnostic paracentesis to rule out spontaneous bacterial peritonitis, which can precipitate hepatorenal syndrome, as recommended by the American Association for the Study of Liver Diseases 6
Liver transplantation remains the definitive treatment for hepatorenal syndrome, as recommended by the American Association for the Study of Liver Diseases 7
Avoid nephrotoxic drugs in patients with advanced cirrhosis to prevent hepatorenal syndrome, as recommended by the European Association for the Study of the Liver 8
Adverse effects of vasoconstrictors include cardiac or intestinal ischemia, pulmonary edema, and distal necrosis, with a strength of evidence level of high 2

Norepinephrine plus albumin is an effective standalone treatment for hepatorenal syndrome, with improvement in renal function observed in 39-70% of patients, comparable to terlipressin plus albumin 9, 10
Norepinephrine is administered at a starting dose of 0.5 mg/h and increased every 4 hours by 0.5 mg/h to a maximum of 3 mg/h, with the goal of increasing mean arterial pressure by 10 mmHg or urine output to >50 mL/h for at least 4 hours 9, 11
Octreotide alone is ineffective for HRS as its splanchnic vasoconstrictive effect is largely counteracted by the numerous vasodilators in the splanchnic circulation 9, 11

Multiple randomized controlled trials comparing norepinephrine to terlipressin have shown similar efficacy in improving renal function in HRS patients 10
The combination of midodrine and octreotide works more slowly than norepinephrine and is considered inferior to both terlipressin and norepinephrine in improving renal function in HRS 9, 11

Norepinephrine traditionally requires ICU monitoring, though a small feasibility study found it could be safely administered outside the ICU 9, 10
Potential adverse effects of norepinephrine include ischemic complications, cardiac arrhythmias, and respiratory side effects 9, 10
Liver transplantation remains the definitive treatment for HRS, and pharmacological therapy should be viewed as a bridge to transplantation 12
TIPS has limited evidence for HRS treatment and cannot currently be recommended as standard therapy 9, 11
Renal replacement therapy should be considered only as a bridge to liver transplantation in patients unresponsive to vasoconstrictor therapy 9, 11